Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene is poised for success with its drug candidates, NGN-401 and NGN-101, which have shown durable and multi-domain improvements in clinical trials with no regression, setting itself apart from competitors who only focus on single-skill gains. With the support of key opinion leaders and a clear responder definition, Neurogene is likely to see success in securing ICV reimbursement, and its runway through 1Q28 provides a promising financial outlook.

Bears say

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. While the company's proprietary EXACT technology may hold promise, the fact that its product pipeline is limited to just two candidates puts it at risk for lack of diversification. In addition, the high cost of developing and obtaining approvals for genetic medicines may pose challenges for Neurogene's financial success.

Neurogene Inc (NGNE) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Neurogene Inc (NGNE) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.